Asia Pacific Peptide Therapeutics Market Size & Outlook
Related Markets
Asia Pacific peptide therapeutics market highlights
- The Asia Pacific peptide therapeutics market generated a revenue of USD 12,937.4 million in 2023.
- The market is expected to grow at a CAGR of 13.7% from 2024 to 2030.
- In terms of segment, metabolic disorders was the largest revenue generating application in 2023.
- Metabolic disorders is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 12,937.4 million |
| Market revenue in 2030 | USD 31,865.6 million |
| Growth rate | 13.7% (CAGR from 2023 to 2030) |
| Largest segment | Metabolic disorders |
| Fastest growing segment | Metabolic disorders |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cancer, Metabolic disorders, Cardiovascular disorders, Respiratory disorders, Gastrointestinal disorders, Infectious disease, Pain, Dermatological disorders, Neurological disorders, Renal disorders |
| Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Amgen Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Sanofi SA, Roche Holding AG, Novartis AG ADR, Novo Nordisk A/S ADR, GlaxoSmithKline, Ironwood Pharmaceuticals Inc Class A, Ipsen SA, Radius Health |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.8% of the global peptide therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 172,089.8 million by 2030.
Metabolic disorders was the largest segment with a revenue share of 59.42% in 2023. Horizon Databook has segmented the Asia Pacific peptide therapeutics market based on cancer, metabolic disorders, cardiovascular disorders, respiratory disorders, gastrointestinal disorders, infectious disease, pain, dermatological disorders, neurological disorders, renal disorders covering the revenue growth of each sub-segment from 2018 to 2030.
The peptide therapeutics market within the Asia Pacific region is anticipated to experience significant expansion over the projected timeframe, primarily due to advancements in healthcare policies across the area. Key contributors to this growth are the rising elderly demographic, enhancements in healthcare facilities, and the entry of innovative companies into the market.
Prominent companies active in this space are GSK plc, AstraZeneca, and Sanofi. In addition, the region's substantial population size contributes to a higher incidence of viral infections. For instance, Singapore, as reported by the Singapore Ministry of Health, faces a considerable challenge from respiratory illnesses such as influenza compared to other health issues.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peptide Therapeutics Market Scope
Peptide Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific peptide therapeutics market size, by country, 2018-2030 (US$M)
Asia Pacific Peptide Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
